Cyclacel Pharmaceuticals, Inc.(NASDAQ : CYCC)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.11%||176.97||0.7%||$1155.61m|
|LLY||Eli Lilly & Co.||-0.82%||368.94||1.1%||$1059.96m|
|MRK||Merck & Co., Inc.||0.51%||110.65||0.7%||$1007.73m|
|BMY||Bristol-Myers Squibb Co.||-0.32%||79.67||1.1%||$739.59m|
|HZNP||Horizon Therapeutics Plc||1.34%||97.59||5.4%||$290.27m|
|IDXX||IDEXX Laboratories, Inc.||1.61%||426.87||3.9%||$194.47m|
|ALNY||Alnylam Pharmaceuticals, Inc.||2.89%||238.01||8.0%||$173.01m|
|NVO||Novo Nordisk A/S||1.92%||127.64||0.1%||$154.96m|
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.